CatalYm to present updated GDFATHER-NEO trial data at ESMO 2026

CatalYm will present updated clinical results from its Phase 2 GDFATHER-NEO trial at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The presentation will include final pathological and radiological outcomes and event-free survival data from the trial in muscle-invasive bladder cancer. Two additional presentations will cover ongoing Phase 2b trials for visugromab in non-small cell lung cancer and hepatocellular carcinoma.